SARS-Cov-2

An immune response may be responsible for “COVID toes,” chilblain-like lesions associated with COVID-19 infection, according to a study published in the British Journal of Dermatology.

Although nearly 70% of U.S. adults said last year’s mild influenza season will not impact their decision to get a vaccine this year, many indicated they would continue pandemic-related precautions through the season, a survey found.

Mucormycosis is an opportunistic fungal infection that manifests in patients with low immunity. Although the fungus spores are ubiquitous in nature and found in the environment, fungal infections rarely occur in immunocompetent individuals.

WHO on Wednesday published a clinical case definition of long COVID that includes 12 domains and 88 words.

The FDA issued an emergency use authorization for a rapid COVID-19 test that it said could dramatically increase at-home testing capacity in the United States.

Johnson & Johnson said Tuesday that it has asked the FDA to authorize a booster dose of its one-shot COVID-19 vaccine for people aged 18 years or older.

Research to develop successful vaccines to help slow the spread of SARS-CoV-2 has taken place very publicly and at a historically fast pace.

The PROVENT study demonstrated that AstraZeneca’s AZD7442 monoclonal antibody cocktail significantly reduced the risk for developing symptomatic COVID-19.

A team of researchers from Seattle and the CDC found that neutralizing antibodies remained detectable in most children 6 months after SARS-CoV-2 infection, waning “to a small degree,” according to results presented at IDWeek.

A 3-day course of IV remdesivir was safe, well tolerated and prevented COVID-19-related hospitalizations among high-risk COVID-19 patients, according to data presented at IDWeek.